TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05391685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scar release techniques + therapeutic ultrasound
Description: Control group will be treated by therapeutic ultrasound only for2 sessions per week for two weeks Study group) will be treated by various scar release techniques in addition to therapeutic ultrasound, 2 sessions per week for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scar release techniques + therapeutic ultrasound
Description: Control group will be treated by therapeutic ultrasound only for2 sessions per week for two weeks Study group) will be treated by various scar release techniques in addition to therapeutic ultrasound, 2 sessions per week for two weeks.
Study: NCT06162169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam , Rosuvastatin calcium and digoxin
Description: Midazolam , Rosuvastatin calcium and digoxin was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin was administered orally
Study: NCT05250843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE/HAIC
Description: Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants received lenvatinib capsules 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver resection
Description: liver resection is feasible after evaluation by the liver cancer surgery expert group
Study: NCT06541886

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: CBT-I was developed as a treatment for adults with insomnia. There are more than 100 studies showing that CBT-I is effective in treating insomnia in adults, and several studies suggest it is also effective in treating insomnia in teens.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: CBT-I was developed as a treatment for adults with insomnia. There are more than 100 studies showing that CBT-I is effective in treating insomnia in adults, and several studies suggest it is also effective in treating insomnia in teens.
Study: NCT05986448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-chi exercise
Description: Traditional Chinese Tai Chi Movement
Study: NCT05398718

Intervention type: DRUG
Intervention: Sotrovimab
Description: collect local clinical evidence for sotrovimab effect in the real-life setting
Study: NCT05388318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged nightly fasting
Description: 14 hour nightly fast from caloric food and beverage; followed by 10 hour eating window. 8-week intervention duration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Weekly health education video viewing related to general health topics
Study: NCT05979545

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Diagnostics
Description: Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
Study: NCT04803123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.
Study: NCT06105671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort
Description: Participants are administered 54 μg Formoterol and 1920 μg Budesonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Participants are administered 54 μg Formoterol from an inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Participants are administered 120 μg Formoterol in a capsule, which is taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are administered placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Participants are administered 600 mg Bronchitol
Study: NCT04796402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: 700 mg/20mL IV over at least one hour OD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care includes primary care and specialist care as indicated by the patient's primary care provider
Study: NCT05200260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery
Description: Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: 3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARP inhibitor
Description: For patients with CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors. In this trial, Niraparib 200mg po qd is suggested after the front-line therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor
Description: For patients with CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors. In this trial, Niraparib 200mg po qd is suggested after the front-line therapy.
Study: NCT06013774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IXSI
Description: Hybrid imaging with IXSI will be performed during the radioembolization pre-treatment procedure
Study: NCT06064760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Workshop on Personal Strengths and Emotional Competences to Improve the Psychological Wellbeing and Quality of Life of Grandparents Caring for Their Grandchildren
Description: The intervention is a psychoeducational group workshop (6-8 participants). It includes 5 sessions of, approximately, 90 minutes. In addition, 3 months after the end of the workshop, a follow-up call will be organized with the participants. Due to the Covid-19 pandemic, the workshop will be held online.~The sessions are:~* Session 1: Defining my role as grandparent.~* Session 2: Deepening my relationships.~* Session 3: Growing as grandparent.~* Session 4: Discovering my emotional world.~* Session 5: Caring for others and caring for myself.
Study: NCT05719922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
Study: NCT05070546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based Vaccine
Description: Participants will receive a single IM injection of an RSV vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based Vaccine
Description: Participants will receive a single IM injection of an RSV vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based Vaccine
Description: Participants will receive a single IM injection of an RSV vaccine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IM injection of matching placebo.
Study: NCT05719922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
Study: NCT06064799

Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA-223 & -214 detection
Description: miRNA-223 \& -214 detection in GCF samples by PCR kits

Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA-223 & -214 detection
Description: miRNA-223 \& -214 detection in GCF samples by PCR kits

Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA-223 & -214 detection
Description: miRNA-223 \& -214 detection in GCF samples by PCR kits
Study: NCT05070546

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IM injection of matching placebo.
Study: NCT04819633

Intervention type: OTHER
Intervention: Determination of serum sestrin levels
Description: Serum sestrin levels will be determined using venous blood samples obtained from the subjects.

Intervention type: OTHER
Intervention: Determination of serum sestrin levels
Description: Serum sestrin levels will be determined using venous blood samples obtained from the subjects.
Study: NCT05854186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth solution: video conferencing
Description: Telehealth solution: video conferencing
Study: NCT05689905

Intervention type: DIAGNOSTIC_TEST
Intervention: HLA typing of the children
Description: The HLA typing is made on a mouth swab of the children, that is a painless non-invasive procedure.

Intervention type: DIAGNOSTIC_TEST
Intervention: HLA typing of the children
Description: The HLA typing is made on a mouth swab of the children, that is a painless non-invasive procedure.
Study: NCT05887999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3532226
Description: Administered subcutaneously (SC).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT05014854

Intervention type: DEVICE
Group type: OTHER
Intervention: Usage of the SensoGrip-System comprised of the SensoGrip pen and a tablet app.
Description: Intervention consists of the usage of the SensoGrip-System in at least 6 and up to 8 therapy session together with the participating child. It is assumed that the standard frequency of therapy sessions is once a week, resuming in a span of 6-8 weeks. 10 minutes of every therapy session during the intervention phase must involve the application of the SensoGrip-System. Sample exercises are made available, therapists can freely choose which exercises are used.
Study: NCT05990595

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adlay with white rice
Description: We will investigate the lipid- and glucose-lowering effects of Adlay rice in comparison to white rice through a randomized cross-over trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: white rice
Description: white rice
Study: NCT05788289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
Study: NCT05857280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE Mollii Suit Stimulation
Description: We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE Mollii Suit Stimulation
Description: We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms.
Study: NCT04993664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen (TQJ230)
Description: The first group will receive pelacarsen. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The second group will receive placebo. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
Study: NCT04927208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and nutritional support
Description: resistance exercise and protein supplementation including branched chain amino acids for 12 weeks~Other: Combined exercise and nutrition intervention resistance exercise and nutritional supplementation for 12 weeks
Study: NCT04054232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High PAD risk Alert
Description: In this message sent via the electronic health record, a participant's primary care physician will receive a message that details the following:~1. Participant flagged as having a high risk of peripheral artery disease based on their electronic health record data~2. What peripheral artery disease is and why diagnosis may be important~3. Recommendation to refer to a vascular medicine specialist or order ankle brachial index for definitive diagnosis~4. The option to opt out if the potential participant is not deemed a candidate for inclusion in the study with a short explanation of why the potential participant should not be included.
Study: NCT05066438

Intervention type: BEHAVIORAL
Intervention: Antenatal hand expression
Description: Standardized counselling and provision of information/resources on the practice of antenatal hand expression to encourage milk let down and colostrum production/collection.
Study: NCT06558877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmacist-led multifaceted intervention
Description: Based on the blood pressure management model of pharmacist-led multifaceted intervention, clinical pharmacists who have received unified training provide pharmaceutical intervention and lifestyle guidance to subjects in the intervention group according to standard protocol.~Pharmaceutical interventions include health education, medication adherence (medication consultation, medication reminder), medication reorganization, and rational use of medication. At the same time, clinical pharmacists supervise the subjects to change their lifestyle (including reasonable diet, quitting smoking and drinking, moderate exercise, weight control and ensuring sleep, etc.), and guide the subjects to conduct home blood pressure monitoring.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional health education
Description: The subjects receive conventional hypertension health education, standard blood pressure measurement training and regular follow-up in the control group.
Study: NCT06445192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Attend group counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive aerobic and resistance exercise intervention via telehealth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Fitbit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear Fitbit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies
Study: NCT06294743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve neuroprolotherapy
Description: Real-time ultrasound guided needle injecting 10ml of 5% dextrose solution around the posterior tibial nerve to elicit a neurostimulatory response.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve neuroprolotherapy
Description: Real-time ultrasound guided needle injecting 10ml of 5% dextrose solution around the posterior tibial nerve to elicit a neurostimulatory response.
Study: NCT06445192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Receive aerobic and resistance exercise intervention via telehealth
Study: NCT06362486

Intervention type: OTHER
Intervention: Severity of infection, time of infection.
Description: Severity of infection, time of infection.

Intervention type: OTHER
Intervention: Mental health assessment
Description: Mental health assessment

Intervention type: OTHER
Intervention: biological
Description: Prognostic immunologic factors associated with cognitive impairment in children born of sars-cov-2-infected mothers.
Study: NCT05491226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg is administered intravenously at Week 1, then every 3 weeks during the treatment period (6 weeks). Therapy will continue for until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy (RT) consists of 8 Gy for 3 fractions over 3 consecutive days at Week 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab 1 mg/kg is administered intravenously weekly starting 1 week post- RT (Week 3). Therapy will continue until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
Study: NCT06303726

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction single bundle
Description: We will do surgery of ACL reconstruction with patellar ligament.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction double bundle
Description: We will do surgery of ACL reconstruction with hamstring ligament.
Study: NCT03337997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: Open Irreversible Electroporation by ultrasound guidance for tumors under 3 cm in diameter. Goal is to obtain an Amp rise of 12 or more
Study: NCT06294743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500Mg Tab
Description: Oral acetaminophen 500mg tab stat, followed by Q6h if needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500Mg Tab
Description: Oral acetaminophen 500mg tab stat, followed by Q6h if needed.
Study: NCT06449274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed. Individual will receive guideline-directed medical treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical treatment
Description: All individuals will receive guideline-directed medical treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-directed medical treatment
Description: All individuals will receive guideline-directed medical treatment.
Study: NCT06492837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab in combination with Zanubrutinib
Description: Combinations of Mosunetuzumab and Zanubrutinib as salvage strategy in patients with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
Study: NCT05689762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle counseling and E-health support
Description: Promotion of healthy lifestyle behaviors through counseling and access to E-health platform